These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21575292)

  • 1. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
    Nunn AJ; Jindani A; Enarson DA;
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):741-5. PubMed ID: 21575292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    Jindani A; Borgulya G; de Patiño IW; Gonzales T; de Fernandes RA; Shrestha B; Atwine D; Bonnet M; Burgos M; Dubash F; Patel N; Checkley AM; Harrison TS; Mitchison D;
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):832-8. PubMed ID: 27155189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions.
    Ukwaja KN; Oshi SN; Alobu I; Oshi DC
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):295-301, i-vii. PubMed ID: 25686137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM; Bakare NA; Onadeko BO
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
    N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.
    Okwera A; Johnson JL; Luzze H; Nsubuga P; Kayanja H; Cohn DL; Nunn P; Ellner JJ; Whalen CC; Mugerwa RD
    Int J Tuberc Lung Dis; 2006 Jan; 10(1):39-44. PubMed ID: 16466035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW; Snider DE; Farer LS
    Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
    Hung NV; Ando H; Thuy TT; Kuwahara T; Hang NT; Sakurada S; Thuong PH; Lien LT; Keicho N
    BMC Res Notes; 2013 Nov; 6():444. PubMed ID: 24188178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The chemotherapy of tuberculous meningitis in children and adults.
    Donald PR
    Tuberculosis (Edinb); 2010 Nov; 90(6):375-92. PubMed ID: 20810322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
    N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
    Ige OM; Sogaolu OM; Odaibo GN; Olaleye OD
    Afr J Med Med Sci; 2004 Sep; 33(3):259-62. PubMed ID: 15819474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.